Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting | ||
By: GlobeNewswire - 04 Mar 2024 | Back to overview list |
|
WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting, which will take place in San Diego, CA from March 8 - 12, 2024. Among these presentations will be late-breaking clinical data on roflumilast cream 0.05% in patients 2 to 5 years of age with mild to moderate atopic dermatitis from the pivotal INTEGUMENT-PED Phase 3 randomized controlled trial. “Our significant presence at this year’s AAD is a testament to our commitment to bringing meaningful innovation in immuno-dermatology, and building on the body of evidence supporting our topical roflumilast development program. In particular, we are excited to be participating in the late breaking data presentations with new results from INTEGUMENT-PED, as part of our atopic dermatitis clinical program,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer, Arcutis. “We appreciate the opportunity to participate in the AAD and other medical meetings to engage with our peers and progress the medical dermatology field.” Presentation details follow:
The following posters will be electronically available for the entirety of the conference and online beginning Friday, March 8, 2024: Pooled Efficacy, Patient-Reported Outcomes, and Safety of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Clinical Trials of Adults and Children With Atopic Dermatitis Roflumilast Foam 0.3% Once Daily in Patients With Seborrheic Dermatitis: Improvement in Patient Reported Outcomes and Pruritus From a Phase 3 Trial (STRATUM) Patient-Reported Outcomes With Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis in the Phase 3 ARRECTOR Trial Roflumilast Cream 0.3% in Patients With Psoriasis: Improvement in Patient Reported Outcomes and Pruritus From Two Pooled Phase 3 Trials (DERMIS-1/DERMIS-2) About Arcutis INDICATIONS ZORYVE foam, 0.3%, is indicated for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. IMPORTANT SAFETY INFORMATION Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application. The most common adverse reactions (?1%) for ZORYVE cream include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%). The most common adverse reactions (?1%) for ZORYVE foam include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%). Please see full Prescribing Information for ZORYVE foam and full Prescribing Information for ZORYVE cream. Forward-Looking Statements Contacts: Investors Derek Cole |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |